CA2324028A1 - Retroviral packaging cell line - Google Patents

Retroviral packaging cell line Download PDF

Info

Publication number
CA2324028A1
CA2324028A1 CA002324028A CA2324028A CA2324028A1 CA 2324028 A1 CA2324028 A1 CA 2324028A1 CA 002324028 A CA002324028 A CA 002324028A CA 2324028 A CA2324028 A CA 2324028A CA 2324028 A1 CA2324028 A1 CA 2324028A1
Authority
CA
Canada
Prior art keywords
packaging cell
cell line
retroviral packaging
compounds
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002324028A
Other languages
French (fr)
Other versions
CA2324028C (en
Inventor
Frederic Bushman
Mark Hansen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Salk Institute for Biological Studies
Original Assignee
The Salk Institute For Biological Studies
Verma, Inder M.
Kafri, Tal
Frederic Bushman
Mark Hansen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Salk Institute For Biological Studies, Verma, Inder M., Kafri, Tal, Frederic Bushman, Mark Hansen filed Critical The Salk Institute For Biological Studies
Priority to CA2604824A priority Critical patent/CA2604824C/en
Publication of CA2324028A1 publication Critical patent/CA2324028A1/en
Application granted granted Critical
Publication of CA2324028C publication Critical patent/CA2324028C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Abstract

The present invention provides packaging cell lines and recombinant lentiviral or retroviral particles produced therefrom, particularly pseudotyped retroviral particles. The packaging cell lines of the invention are produced by inducibly expressing an envelope protein by methods described herein. Also described is a screening assay for compounds that affect integration of viral nucleic acid into target (e.g., host) nucleic acid. Such compounds are identified based on their effect on viral integrase.
CA002324028A 1998-03-18 1999-03-18 Retroviral packaging cell line Expired - Fee Related CA2324028C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2604824A CA2604824C (en) 1998-03-18 1999-03-18 Retroviral packaging cell line

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4408598A 1998-03-18 1998-03-18
US09/044,085 1998-03-18
US09/148,575 US6218181B1 (en) 1998-03-18 1998-09-03 Retroviral packaging cell line
US09/148,575 1998-09-03
PCT/US1999/005982 WO1999047660A1 (en) 1998-03-18 1999-03-18 Retroviral packaging cell line

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2604824A Division CA2604824C (en) 1998-03-18 1999-03-18 Retroviral packaging cell line

Publications (2)

Publication Number Publication Date
CA2324028A1 true CA2324028A1 (en) 1999-09-23
CA2324028C CA2324028C (en) 2008-01-08

Family

ID=26721161

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002324028A Expired - Fee Related CA2324028C (en) 1998-03-18 1999-03-18 Retroviral packaging cell line

Country Status (6)

Country Link
US (2) US6218181B1 (en)
EP (1) EP1064363A1 (en)
JP (1) JP2002506641A (en)
AU (1) AU3100699A (en)
CA (1) CA2324028C (en)
WO (1) WO1999047660A1 (en)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5888767A (en) * 1996-11-27 1999-03-30 The Johns Hopkins University School Of Medicine Method of using a conditionally replicating viral vector to express a gene
US6908770B1 (en) * 1998-07-16 2005-06-21 Board Of Regents, The University Of Texas System Fluid based analysis of multiple analytes by a sensor array
US6613569B1 (en) * 1999-05-25 2003-09-02 University Of Medicine And Dentistry Of New Jersey Inducible packaging cell lines for lentivirus vectors
EP1349959A2 (en) * 2000-10-10 2003-10-08 The Regents Of The University Of California Assay to detect integration of a retrovirus polynucleotide into a target nucleic acid
US7575924B2 (en) 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
US20030026791A1 (en) * 2001-03-27 2003-02-06 Laurent Humeau Conditionally replicating vectors for inhibiting viral infections
US7629153B2 (en) 2001-08-02 2009-12-08 Research Development Foundation Methods and compositions relating to improved lentiviral vector production systems
AU2002330022B2 (en) 2001-09-13 2007-07-12 California Institute Of Technology Method for producing transgenic birds and fish
EP1424896B1 (en) 2001-09-13 2016-08-03 California Institute Of Technology Method for expression of small rna molecules within a cell
KR20040054699A (en) * 2001-10-02 2004-06-25 엥스띠뛰 끌레이톤 드 라 러쉐르쉬 Methods and compositions relating to restricted expression lentiviral vectors and their applications
AU2002351884B2 (en) * 2001-12-24 2008-09-18 Es Cell International Pte Ltd Method of transducing ES cells
EP1468094A4 (en) * 2001-12-24 2005-01-26 Es Cell Int Pte Ltd Method of transducing es cells
ATE358681T1 (en) * 2002-02-05 2007-04-15 Geymonat Spa METHOD FOR RECOMBINANT PRODUCTION OF PLACENTA GROWTH FACTOR
US8257967B2 (en) * 2002-04-26 2012-09-04 Board Of Regents, The University Of Texas System Method and system for the detection of cardiac risk factors
CA2491212A1 (en) * 2002-06-26 2004-01-08 Biogen Idec Ma Inc. Protein production methods and modified cells for use therein
AU2003302724A1 (en) * 2002-08-13 2004-07-09 Mcivor, Scott, R. Methods of using vectors to treat metabolic disorders
CN1759182A (en) * 2002-11-22 2006-04-12 克雷顿研究院 Compositions and systems for the regulation of genes
EP1624899B1 (en) * 2003-05-05 2010-11-17 VIRxSYS Corporation INCREASED TRANSDUCTION USING ABC TRANSPORTER SUBSTRATES that are INHIBITORS
WO2006031210A1 (en) * 2003-05-29 2006-03-23 Board Of Regents, The University Of Texas Systems Jabi as a prognostic marker and a therapeutic target for human cancer
WO2004106517A1 (en) * 2003-06-03 2004-12-09 Benitec Australia Limited Double-stranded nucleic acid
WO2005037218A2 (en) * 2003-10-17 2005-04-28 Actis Biologics, Inc. Lentiviral vector delivery of il-21 for treatment of cancer
AU2004300168A1 (en) * 2003-12-11 2005-06-30 Board Of Regents, The University Of Texas System Method and system for the analysis of saliva using a sensor array
US20060134612A1 (en) * 2004-02-10 2006-06-22 Frederic Bushman Methods and compositions for retroviral preintegration complex-based assays
US8105849B2 (en) * 2004-02-27 2012-01-31 Board Of Regents, The University Of Texas System Integration of fluids and reagents into self-contained cartridges containing sensor elements
US8101431B2 (en) 2004-02-27 2012-01-24 Board Of Regents, The University Of Texas System Integration of fluids and reagents into self-contained cartridges containing sensor elements and reagent delivery systems
EP1725660B1 (en) 2004-03-05 2011-05-04 Benitec, Inc. Multiple promoter expression cassettes for simultaneous delivery of rnai agents
DE102004034461B4 (en) * 2004-07-16 2008-02-07 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Gene Therapy of Solid Tumors by Retroviral Arenavirus Glycoprotein-Pseudotyped Vectors
US20070036740A1 (en) * 2004-10-06 2007-02-15 Reed Kenneth C Modulation of hair growth
US20060115455A1 (en) * 2004-10-22 2006-06-01 Reed Kenneth C Therapeutic RNAi agents for treating psoriasis
US20070004040A1 (en) * 2005-01-06 2007-01-04 Brashears Sarah J RNAi agents for maintenance of stem cells
CA2596711C (en) * 2005-02-03 2015-12-15 Benitec, Inc. Rnai expression constructs
MX2007010008A (en) 2005-02-16 2008-01-18 Lentigen Corp Lentiviral vectors and their use.
US8008468B2 (en) * 2005-02-16 2011-08-30 Benitec, Inc. RNAi expression constructs with liver-specific enhancer/promoter
EP1874794A4 (en) * 2005-04-28 2009-07-29 Benitec Ltd Multiple-rnai expression cassettes for simultaneous delivery of rnai agents related to heterozygotic expression patterns
AU2006309284B2 (en) 2005-05-31 2012-08-02 Board Of Regents, The University Of Texas System Methods and compositions related to determination and use of white blood cell counts
AU2006252406B2 (en) 2005-06-01 2012-05-17 California Institute Of Technology Method of targeted gene delivery using viral vectors
WO2007002480A2 (en) * 2005-06-24 2007-01-04 Board Of Regents, The University Of Texas System Systems and methods including self-contained cartridges with detection systems and fluid delivery systems
PT2048955E (en) 2006-07-21 2013-09-20 California Inst Of Techn Targeted gene delivery for dendritic cell vaccination
WO2008069663A1 (en) 2006-12-07 2008-06-12 Publiekrechtelijke Rechtspersoon Academisch Ziekenhuis Leiden H.O.D.N. Leids Universitair Medisch Centrum Use of a varicellovirus tap-inhibitor for the induction of tumor- or virus-specific immunity against teipp
WO2008136790A1 (en) 2007-05-02 2008-11-13 Merial Limited Dna plasmids having improved expression and stability
WO2010087702A1 (en) 2009-01-30 2010-08-05 Stichting Katholieke Universiteit TET2 gene as a marker for diagnosing a myelodysuplastic syndrome (MDS) or an acute myeloid leukemia (AML) and determining the prognosis in a subject
EP3061808B1 (en) 2009-02-03 2020-08-12 Koninklijke Nederlandse Akademie van Wetenschappen Culture medium for epithelial stem cells and organoids comprising said stem cells
EP2412800A1 (en) 2010-07-29 2012-02-01 Koninklijke Nederlandse Akademie van Wetenschappen Liver organoid, uses thereof and culture method for obtaining them
US9752124B2 (en) 2009-02-03 2017-09-05 Koninklijke Nederlandse Akademie Van Wetenschappen Culture medium for epithelial stem cells and organoids comprising the stem cells
US9200276B2 (en) 2009-06-01 2015-12-01 Halo-Bio Rnai Therapeutics, Inc. Polynucleotides for multivalent RNA interference, compositions and methods of use thereof
SI2770061T1 (en) 2009-07-24 2019-02-28 Immune Design Corp. Non-integrating lentiviral vectors
JP2013505232A (en) 2009-09-16 2013-02-14 スティヒティング ヘット ネーデルラント カンカー インスティテュート Fra-1 target gene as a drug target for cancer therapy
EP2305717A1 (en) 2009-09-21 2011-04-06 Koninklijke Nederlandse Akademie van Wetenschappen Inhibiting TNIK for treating colon cancer
EP2521789B1 (en) 2010-01-08 2016-12-14 Immusoft Corporation Vectors and methods for transducing b cells
CN101935675B (en) * 2010-01-14 2012-06-06 山东农业大学 Construction and application of cell membrane expression ALV-env fluorescin eukaryotic transgenic expression plasmid
US20110237653A1 (en) * 2010-03-28 2011-09-29 Scheiber Lane Bernard Rna vector therapy method
US20110236483A1 (en) * 2010-03-28 2011-09-29 Scheiber Lane Bernard Rna vector therapy
US9309534B2 (en) 2010-07-12 2016-04-12 Universidad Autonoma De Barcelona Gene therapy composition for use in diabetes treatment
WO2012047093A1 (en) 2010-10-05 2012-04-12 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Treatment of the sjögren's syndrome
DK3124610T3 (en) 2010-10-28 2019-06-11 Benitec Biopharma Ltd HBV TREATMENT
EP2465928A1 (en) 2010-12-16 2012-06-20 Academisch Medisch Centrum bij de Universiteit van Amsterdam Treatment of Th17-mediated diseases
US9567649B2 (en) 2011-04-28 2017-02-14 Jørn Erland Koch System for identification of microorganism and detection of infectious disease
GB201202516D0 (en) 2012-02-13 2012-03-28 Ucl Business Plc Materials and methods relating to packaging cell lines
US8323662B1 (en) 2012-03-30 2012-12-04 Immune Design Corp. Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein
US9713635B2 (en) 2012-03-30 2017-07-25 Immune Design Corp. Materials and methods for producing improved lentiviral vector particles
DK2831095T3 (en) 2012-03-30 2019-02-18 Immune Design Corp LENTIVIRAL VECTOR PARTICLES WITH IMPROVED TRANSDUCTION EFFICIENCY FOR CELL EXPRESSING DC SIGN
US9943574B2 (en) 2012-06-27 2018-04-17 Arthrogen B.V. Combination for treating an inflammatory disorder
PT2852668T (en) 2012-07-12 2016-07-13 Proqr Therapeutics Ii Bv Oligonucleotides for making a change in the sequence of a target rna molecule present in a living cell
EP2692868A1 (en) 2012-08-02 2014-02-05 Universitat Autònoma De Barcelona Adeno-associated viral (AAV) vectors useful for transducing adipose tissue
PT2971039T (en) 2013-03-14 2020-05-06 Immusoft Corp Methods for in vitro memory b cell differentiation and transduction with vsv-g pseudotyped viral vectors
AU2014239954B2 (en) 2013-03-15 2020-07-16 The Jackson Laboratory Isolation of non-embryonic stem cells and uses thereof
EP3234107B1 (en) 2014-12-19 2022-09-14 Immusoft Corporation B cells for in vivo delivery of therapeutic agents
EP3242945B1 (en) 2015-01-07 2021-09-01 Universitat Autònoma de Barcelona Single-vector gene construct comprising insulin and glucokinase genes
AU2016312530A1 (en) 2015-08-24 2018-03-01 Halo-Bio Rnai Therapeutics, Inc. Polynucleotide nanoparticles for the modulation of gene expression and uses thereof
CN115105500A (en) 2015-10-23 2022-09-27 杰克逊实验室 Nicotinamide for treating and preventing neurodegenerative diseases of the eye such as glaucoma
EP3738973A1 (en) 2015-11-09 2020-11-18 Immune Design Corp. Compositions comprising lentiviral vectors expressing il-12 and methods of use thereof
US11135283B2 (en) 2015-11-09 2021-10-05 Immune Design Corp. Retroviral vector for the administration and expression of replicon RNA expressing heterologous nucleic acids
US11208669B2 (en) 2016-01-12 2021-12-28 University Of Cincinnati Lentivirus packaging system comprising a synthetic positive feedback loop
BR112018016986A2 (en) 2016-02-23 2019-02-05 Immune Design Corp multigenomic retroviral vector preparations and methods and systems for their preparation and use
CA3027124A1 (en) 2016-06-10 2017-12-14 Umc Utrecht Holding B.V. Novel method for identifying deltat-cell (or gammat-cell) receptor chains or parts thereof that mediate an anti-tumour or an anti-infective response
CA3050917A1 (en) 2017-01-30 2018-08-02 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant virus vectors for the treatment of glycogen storage disease
WO2018148180A2 (en) 2017-02-07 2018-08-16 Immune Design Corp. Materials and methods for identifying and treating cancer patients
JP2020530977A (en) 2017-05-24 2020-11-05 ウニベルシダッド アウトノマ デ バルセロナ Viral expression construct containing fibroblast growth factor 21 (FGF21) coding sequence
CA3086765A1 (en) 2017-12-28 2019-07-04 Tract Pharmaceuticals, Inc. Stem cell culture systems for columnar epithelial stem cells, and uses related thereto
JP2021515576A (en) 2018-03-16 2021-06-24 イミュソフト コーポレーション B cells genetically engineered to secrete follistatin and methods of using it to treat follistatin-related diseases, conditions, disorders, and to enhance muscle growth and strength.
WO2019219979A1 (en) 2018-05-18 2019-11-21 Umc Utrecht Holding B.V. Compositions and methods for cell targeting therapies
MX2021005824A (en) 2018-11-26 2021-10-13 UNIV AUTòNOMA DE BARCELONA Fibroblast growth factor 21 (fgf21) gene therapy.
CN113891726A (en) 2019-05-31 2022-01-04 巴塞罗那自治大学 Insulin gene therapy
AU2021281506A1 (en) 2020-05-26 2023-02-02 Universitat Autònoma De Barcelona Fibroblast growth factor 21 (FGF21) gene therapy for central nervous system disorders
JP2023540098A (en) 2020-09-03 2023-09-21 チェン アーヴィン エス．ワイ． Soluble alkaline phosphatase construct and expression vector comprising a polynucleotide encoding the soluble alkaline phosphatase construct
EP4259777A1 (en) 2020-12-10 2023-10-18 Sarepta Therapeutics, Inc. Suspension mode seed train development for adherent cells
EP4284440A1 (en) 2021-01-30 2023-12-06 Universitat Autònoma De Barcelona Gene therapy for monogenic diabetes
WO2022221462A1 (en) 2021-04-13 2022-10-20 Kriya Therapeutics, Inc. Vector constructs for delivery of nucleic acids encoding therapeutic vlcad or mcad and methods of using the same
EP4089171A1 (en) 2021-05-12 2022-11-16 Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Recombinant tert-encoding viral genomes and vectors
WO2022258606A1 (en) 2021-06-07 2022-12-15 Gadeta B.V. Delta T-cell or Gamma T-cell receptor chains or parts thereof that mediate an anti-tumour or anti-infective response
WO2023285700A1 (en) 2021-07-16 2023-01-19 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Oligonucleotide for inhibiting quaking activity
WO2023212683A1 (en) 2022-04-29 2023-11-02 Kriya Therapeutics, Inc. Insulin and glucokinase gene therapy compositions and its use for treating diabetes
WO2023227594A1 (en) 2022-05-24 2023-11-30 Gadeta Bv Novel deltat-cell receptor chains, gammat-cell receptor chains, or parts thereof
WO2023237541A1 (en) 2022-06-07 2023-12-14 Gadeta B.V. Delta t-cell or gamma t-cell receptor chains or parts thereof that mediate an anti-tumour or anti-infective response
WO2024013401A1 (en) 2022-07-15 2024-01-18 Gadeta B.V. Novel method for identifying gamma t-cell (or delta t-cell) receptor chains (or gammadelta t-cell receptors) or fragments thereof that mediate an anti-tumour or an anti-infective response
WO2024052413A1 (en) 2022-09-07 2024-03-14 Universitat Autònoma De Barcelona Beta-hexosaminidase vectors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591624A (en) 1988-03-21 1997-01-07 Chiron Viagene, Inc. Retroviral packaging cell lines
JP3082204B2 (en) 1988-09-01 2000-08-28 ホワイトヘッド・インスティチュート・フォー・バイオメディカル・リサーチ Recombinant retrovirus with an amphotropic and ecotropic host range
US5665577A (en) 1989-02-06 1997-09-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
GB8923123D0 (en) 1989-10-13 1989-11-29 Connaught Lab A vaccine for human immunodeficiency virus
EP0496794A1 (en) 1989-10-16 1992-08-05 Whitehead Institute For Biomedical Research Non-infectious hiv-1 particles and uses therefor
JP3264281B2 (en) 1990-06-20 2002-03-11 デイナ・フアーバー・キヤンサー・インステイテユート Vector containing HIV packaging sequence, HIV-defective packaging vector and use thereof
US5817491A (en) 1990-09-21 1998-10-06 The Regents Of The University Of California VSV G pseusdotyped retroviral vectors
US5470726A (en) 1991-02-22 1995-11-28 Fred Hutchinson Cancer Research Center Retrovirus packaging and producer cell lines based on gibbon ape leukemia virus
AU671101B2 (en) 1992-02-28 1996-08-15 Syngenix Limited Defective packaging non-oncoviral vectors based on MPMV
AU678152B2 (en) 1992-03-27 1997-05-22 Whitehead Institute For Biomedical Research Non-infectious HIV particles and uses therefor
TW258789B (en) 1992-09-28 1995-10-01 Rohm & Haas
JPH06261764A (en) 1993-02-17 1994-09-20 Wisconsin Alumni Res Found Mixed ltr containing super complex retrovirus and method for use thereof
US5834256A (en) 1993-06-11 1998-11-10 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
US5576201A (en) 1994-01-14 1996-11-19 Alexion Pharmaceuticals, Inc. Retroviral vector particles for transducing non-proliferating cells
US5750396A (en) 1995-05-08 1998-05-12 St. Judes Children's Research Hospital Stable virus packaging cell lines
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells

Also Published As

Publication number Publication date
US20010009772A1 (en) 2001-07-26
CA2324028C (en) 2008-01-08
JP2002506641A (en) 2002-03-05
WO1999047660A1 (en) 1999-09-23
WO1999047660A9 (en) 2000-05-04
AU3100699A (en) 1999-10-11
EP1064363A1 (en) 2001-01-03
US6727058B2 (en) 2004-04-27
US6218181B1 (en) 2001-04-17

Similar Documents

Publication Publication Date Title
CA2324028A1 (en) Retroviral packaging cell line
ATE147758T1 (en) RECOMBINANT HIV-1 ANTIGENS DERIVED FROM SYNTHETIC DNA
AU7360198A (en) Methods for the production of aslv reverse transcriptases composed of multiple subunits
AU4712397A (en) Lentiviral vectors
AU4712297A (en) Retroviral vectors
AU1689297A (en) Chemokine receptors 88-2B(CKR-3) and 88C and their antibodies
EP1475442A3 (en) Polypeptides of feline T-cell lymphotropic lentivirus
CA2413156A1 (en) Expression vectors
AU7117496A (en) Peptide inhibitor for viral protease derived from the transframe region of the gag-pol gene
CA2166291A1 (en) Htlv-iinra compositions and assays for detecting htlv infection
WO2000000600A3 (en) Lentiviral vectors, comprising modified major donor splice sites and major packaging signals
Pfrepper et al. Molecular characterization of proteolytic processing of the Gag proteins of human spumavirus
EP2305818A3 (en) Antigen constructs useful in the detection and differentiation of antibodies to HIV
WO2001044809A3 (en) Evaluation of biological agents in living target cells
DE69534948D1 (en) RETROVIRAL VECTORS FOR EXPRESSION IN EMBRYONAL CELLS
AU7828698A (en) Detection of loss of the wild-type (hu)bub1 gene
NO951315D0 (en) Increased production of secreted proteins from recombinant eukaryotic cells
ES2157435T3 (en) PSEUDOTIPATED RETROVIRIC PARTICLES.
AU2190288A (en) Vector for the expression of proteins of the HIV-2 virus, one of the casual agents of AIDS, cell culture infected or transformed by this vector, proteins obtained, vaccine and antibodies obtained
WO1996040763A3 (en) Peptides for hiv-1 detection
CA2155001A1 (en) Htlv-i and htlv-ii gp21 derived peptides for use in diagnostics
AU2890495A (en) Nucleic acid fragments and corresponding peptide fragments from the caprine arthritis-encephalitis virus (caev) genome, and uses thereof
WO2002034929A3 (en) Expression vectors and uses thereof
WO2001042500A3 (en) Testing xenografts and sources thereof for retrovirus
EP0829535A4 (en) Cells producing recombinant retrovirus

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20150318